Blood natural killer cells during treatment in recurrent ovarian cancer.

Jon Røikjaer HenriksenLine NederbyFrede DonskovMarianne WaldstrømParvin AdimiAnders JakobsenKarina Dahl Steffensen

Published in: Acta oncologica (Stockholm, Sweden) (2020)

A low blood NK cell count in recurrent metastatic ovarian cancer during chemotherapy is associated with unfavorable prognostic impact. Early increase in survival difference based on NK cell status suggests an association between NK cell count and treatment benefit.

Keyphrases

nk cells
natural killer cells
squamous cell carcinoma
peripheral blood
small cell lung cancer
locally advanced
combination therapy
rectal cancer
replacement therapy